GtoPdb Ligand ID: 7378

Compound class: Antibody
Comment: IMCgp100 is an immunotherapeutic antibody/peptide fusion, comprising a soluble T cell receptor (TCR) specific for the HLA-A2 restricted melanoma-associated antigen gp100, fused to an anti-CD3 single chain antibody fragment (scFv) [1,3]. This belongs to a novel class of immunotherapeutics termed ImmTACs (Immune Mobilising mTCR against Cancer) which are designed to override immune tolerance to cancer and mobilise T cells to kill cancer cells.
No information available.
Summary of Clinical Use
This potential therapeutic is in clinical trial for the treatment of advanced stage malignant melanoma. Although the assessment group was small, the preliminary results of Phase I/II trials have been encouraging, with the therapy showing good tolerability and tumour volume reduction in some patients. Click here to link to's complete list of clinical trials assessing IMCgp100 as a cancer treatment.